Immunic Lays Out Catalyst-Rich Path to Market for Lead MS Drug in Updated Investor Deck

summarizeSummary

Immunic's updated investor presentation charts a clear regulatory course for its lead MS drug, with pivotal Phase 3 data due by end of 2026 and an NDA submission in mid-2027. A Phase 3 trial in progressive MS is also slated to begin later this year.

check_boxKey Events · Product Development and Regulatory · IMUX

• Phase 3 ENSURE Data by Year-End 2026

  Fully enrolled with a combined 2,221 patients, both ENSURE-1 and ENSURE-2 trials in relapsing MS are on track to deliver top-line results by the end of 2026.

• NDA Submission Targeted for Mid-2027

  Assuming positive ENSURE data, a New Drug Application is planned for submission in the U.S. by mid-2027, setting the stage for potential approval in 2028.

• Phase 3 Progressive MS Trial Initiation in 2026

  Encouraged by Phase 2 CALLIPER data that signaled disability improvement, the company expects to launch a Phase 3 trial in progressive MS later this year.

• Cash Runway into Late 2027

  Financial guidance is reiterated, with the current funding position expected to support operations into late 2027, comfortably covering the pivotal ENSURE readout.

auto_awesomeAnalysis · IMUX · Life Sciences

An updated investor presentation from Immunic maps out the road to market for vidofludimus calcium in multiple sclerosis. With both Phase 3 ENSURE trials in relapsing MS fully enrolled, top-line data are expected by year-end 2026, paving the way for a mid-2027 NDA submission and potential U.S. approval in 2028. The deck also reveals plans to kick off a Phase 3 trial in progressive MS later this year, broadening the drug's commercial reach. For a company with a $199M market cap and a cash runway into late 2027, these timelines turn the next 18 months into a decisive value-inflection window.